PDF(Pubmed)
Abstract：
The triglyceride-glucose (TyG) index, proven to be a crucial insulin resistance biomarker (better than the Homeostasis Model Assessment for Insulin Resistance), is simple and non-invasive. Recently, indisputable evidence has shown that the TyG index is strongly associated with cardiovascular disease [CVD, including atherosclerosis, heart failure (HF), and hypertension] prognosis and mortality. Nevertheless, the value of the TyG index in HF patients treated with sodium-glucose cotransporter 2 inhibitors (SGLT2is) has not been systematically evaluated. Therefore, in this review, we summarized the value of the TyG index and its related parameters as markers of CVD, especially HF. Furthermore, we addressed the use of SGLT2is and GLP-1 receptor antagonists in HF patients. Finally, we summarized the mechanism of the \"obesity paradox.\"
摘要：
甘油三酯-葡萄糖(TyG)指数,被证明是一个关键的胰岛素抵抗生物标志物（比胰岛素抵抗的稳态模型评估更好），是简单和非侵入性的。最近,无可争议的证据表明，TyG指数与心血管疾病[CVD，包括动脉粥样硬化,心力衰竭(HF),和高血压]预后和死亡率。然而，TyG指数在接受钠-葡萄糖协同转运蛋白2抑制剂(SGLT2is)治疗的HF患者中的价值尚未得到系统评估.因此,在这次审查中,我们总结了TyG指数及其相关参数作为CVD标志物的价值，尤其是HF。此外，我们讨论了SGLT2is和GLP-1受体拮抗剂在HF患者中的应用.最后,我们总结了“肥胖悖论”的机制。\"
